Greif's CEO, Ole Rosgaard, sees the acquisition as a crucial step in their Build to Last strategy, unlocking new capabilities and market opportunities. The company aims to drive benefits, support growth, and capture $7 million of synergies through Ipackchem's integration.
Insider selling of shares, particularly below current price, is seen as negative, implying a lower price is reasonable. High insider ownership in Greif may suggest management's consideration for shareholder interests. The absence of insider transactions in the past three months is not confidence-inspiring.
The low P/E ratio of Greif, Inc. might be due to expected EPS slump. Investors may not see earnings improvement potential to justify a higher P/E ratio, possibly limiting future share price growth.
High debt carried by the company raises concerns given the substantial reliance on borrowed funds. When considering ROE, other indicators such as profit growth rates and stock pricing must also be evaluated.
Insider transactions indicate mixed sentiment: high level of insider ownership may imply alignment with shareholder interests. However, the share sales, particularly below current prices, may signal lack of confidence in future prospects.
shy Cheetah_0241
lightfoot
:
What the hell they beat all expectations adding a billion to the next quarter. Opened a new mill and there price is down 7%. I will buy the dip and hope for the best I guess. Am I missing something here?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Greif Stock Forum
$Cirrus Logic (CRUS.US)$ $Green Plains Inc (GPRE.US)$ $Hitek Global (HKIT.US)$ $Greif (GEF.US)$
📊⚡️📊
• $Signet Jewelers (SIG.US)$ +7.6% (In reaction to earnings/guidance)
• $Oxford Industries (OXM.US)$ +6.3% (In reaction to earnings/guidance)
• $BridgeBio Pharma (BBIO.US)$ +5%(to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference)
• $Greif (GEF.US)$ +4.6% (In reaction to earnings/guidance)
• $Olema Pharmaceuticals (OLMA.US)$ +4.3% (an...
• $Red Robin (RRGB.US)$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals (PMVP.US)$ +11.2% (ASCO-related announcement)
• $Sumo Logic (SUMO.US)$ +10.8% (In reaction to earnings)
• $Adicet Bio (ACET.US)$ +9.6% (ASCO-related announcement)
• $Dell Technologies (DELL.US)$ +9.6% (In reaction to earnings)
• $ImmunoGen (IMGN.US)$ +8.7% (ASCO-related announcement)
• $Ulta Beauty (ULTA.US)$ +7.9% (In reaction to earnings)
• $Zymergen (ZY.US)$ +7.8% (to...
• $Boot Barn Holdings (BOOT.US)$ : Baird Upgrades to Outperform from Neutral - PT $115
• $Boston Scientific (BSX.US)$ : Needham Upgrades to Buy from Hold - PT $48
• $Graphic Packaging (GPK.US)$ : BMO Capital Upgrades to Outperform from Market Perform - PT $25 (from $20)
• $HCA Healthcare (HCA.US)$ : Bernstein Upgrades to Outperform from Market Perform - PT $271
• $iQIYI (IQ.US)$ : Citigroup Upgrades to Buy from Neutral - PT $5 (from $4.50)
• $Macy's (M.US)$ : Morgan ...
No comment yet